POSTER SESSION V
Wednesday, March 5, 2008 — 9:30 AM - 12:00 Noon
Convention Center Exhibit Hall A
Click on the blue numbers in parentheses to display abstracts.
Click the button next to any title to add to Itinerary Planner...
BREAST PATHOLOGY
Poster#
Title and Authors
Itinerary Planner
1
Clinicopathologic Analysis of ER/PR Positive and HER2/neu Positive Breast Carcinoma
(103)
M Bui, C Laronga, S Hoover, G Acs - H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL
HER-2/neu Splicing Variant Expression in Human Breast Cancer: Comparison of RT-PCR and Immunohistochemistry and Fluorescence In Situ Hybridization
(206)
H Nozaka, R Kazama, H Kouga, A Muramatsu, C Arai, Z Zheng, T Miura, K Kasai, T Sato, E Okusawa, Y Katayama, N Uesugi, T Sugai, S Nakamura - Hirosaki University, Hirosaki, Aomori, Japan; Hokkaido P.W.F.A.C Obihiro-Kosei General Hospital, Obihiro, Hokkaido, Japan; Hachinohe City Hospital, Hachinohe, Aomori, Japan; Iwate Medical University, Morioka, Iwate, Japan
Analysis of Chromosomal Imbalance Patterns in ERBB2 Positive Breast Cancer Using Comparative Genomic Hybridization and Correlation with Chromogenic In Situ Hybridization for Genes ERBB2, C-MYC, TOP2A, and CCND1
(75)
FJ Andreu, R Carrera, A Saez, MA Rigola, JA Vazquez, S Fernandez, M Sentis, M Rey - UDIAT-Centre Diagnostic (Corporacio Parc Tauli), Sabadell (Barcelona), Spain; Universidad Autonoma Barcelona, Barcelona, Spain
Expression of HER-2/neu Splice Variants in the Human Breast Cancer Cells
(76)
C Arai, T Miura, K Kasai, M Chiba, H Nozaka, R Kazama, A Muramatsu, T Sato - Hirosaki University, Hirosaki, Aomori, Japan; University of Tsukuba, Tsukuba, Ibaraki, Japan
Comparative Evaluation of the HER-2 Gene Status in Breast Carcinoma with Immunohistochemistry, Chromogenic In Situ Hybridization and Real-Time Quantitative PCR
(229)
A Rousseau, B Marie, N Martinet, E Ventard, N Weinbreck, A Bressenot, K Montagne, A Leroux, JM Vignaud - Nancy University Hospital, Nancy, France; INSERM, Nancy, France; CLCC Alexis Vautrin, Vandoeuvre-les-Nancy, France
Performance Comparison of a Digital Pathology Solution for IHC to Conventional Manual Microscopy: A Feasibility Study Using 20 HER2 Stained Breast Specimens
(243)
PK Shitabata, EF Glassy, RA Moore, AK Lui, ER Heyman, AH Olson, H Lange - Pathology Inc, Torrance, CA; Aperio Technologies Inc, Vista, CA
HER2 Status in a Large, Population-Based Cohort: Analysis of Distinct HER2 Subgroups
(167)
KC Jensen, DA Turbin, S Leung, MA Miller, K Johnson, B Norris, T Hastie, S McKinney, TO Nielsen, DG Huntsman, CB Gilks, RB West - Stanford University Medical Center, Stanford, CA; University of British Columbia, Vancouver, BC, Canada; Stanford University, Stanford, CA; British Columbia Cancer Research Centre, Vancouver, BC, Canada
Concordance of the Her-2/neu Status in Paired Primary and Metastatic Breast Cancers: Should We Retest the Metastatic Tumors?
(208)
G Omeroglu, P Heinmoeller, J Ruschoff, W Hanna - Sunnybrook Health Sciences Centre, University of Toronto, Canada; TARGOS Molecular Pathology, Kassel, Germany; Institute of Pathology, Klinikum Kassel, Germany
HER2 Testing: IHC, CISH and RT-PCR Correlation Study
(127)
I Frahm, G Acosta Haab, S Sarancone, M Gutierrez, V Caceres - Sanatorio Mater Dei, Buenos Aires, Argentina; Hospital María Curie, Buenos Aires, Argentina; Laboratorio Quantum, Rosario, Santa Fe, Argentina; FUNCEI, Buenos Aires, Argentina; Productos Roche, Tigre, Buenos Aires, Argentina
HER2 Heterogeneity in Primary Breast Cancers: A Tissue Micro-Array Analysis of FISH and IHC
(233)
AO Safo, M Dolan, C Sweeney, C Blair, C Forster, HE Gulbahce - University of Minnesota, Minneapolis, MN; University of Utah, Salt Lake City, UT
Comparison of Automated Silver Enhanced In Situ Hybridization and Fluorescent In Situ Hybridization for Assessment of Her2/neu Gene Status in Invasive Breast Carcinomas
(172)
HJ Kahn, Z Ghorab, K Kwok, W Hanna - Sunnybrook Health Sciences Centre, University of Toronto, Canada
Analysis of Staining Heterogeneity and Level of Amplification in Breast Carcinomas with "2+" HER-2 Immunoreactivity
(258)
DW Visscher, M Reinholtz, D Hillman, R Jenkins, E Perez - University of Michigan Health Systems, Ann Arbor, MI; Mayo Clinic, Rochester, MN; Mayo Clinic, Jacksonville, FL
A Comparison of a New Technology Against the Established Protocols for HER2 Gene Assessment Using Tissue Microarrays
(117)
S Di Palma, N Collins, M Mottolese, A Sapino, F Novelli, C Faulkes, B Ping, M Cook - RSCH, University of Surrey, Guildford, Surrey, United Kingdom
Using a Higher Cutoff for the Percentage of HER2-Positive Cells Decreases Interobserver Variability in the Interpretation of HER2 Immunohistochemistry
(151)
O Hameed, AL Adams, HN Burford, NE Balmer, AC Baker, WC Bell, NC Jhala, T Winokur, MJ Klein, DC Chhieng - University of Alabama School of Medicine, Birmingham, AL
Are ER and HER2/neu the Only Independent Markers of Overall Survival?
(155)
W Hanna, S Nofech-Mozes, S Narod - Sunnybrook Health Sciences Centre, Toronto, Canada; Women's College Research Institute, University to Toronto, Canada
Effect of Immunohistochemistry -Equivocal Breast Carcinomas on Performance of Chromogenic In Situ Hybridization and Inter-Site Reproducibility
(139)
Y Gong, W Sweet, YJ Duh, L Greenfield, S Trivedi, WF Symmans, J Isola, N Sneige - UT M. D. Anderson Cancer Center, Houston, TX; Invitrogen Corporation, Camarillo, CA; StatServ Consulting, Inc., Chino Hills, CA; Institute of Medical Technology, University of Tampere, Tampere, Finland
Co-Expression of Cytoplasmic E-Cadherin and C-erbb2: Implications for Breast Tumor Invasion
(255)
TN Vinh, MY Tata, YG Man - Armed Forces Institute of Pathology and American Registry of Pathology, Washington, DC
Poor Prognostic Significance of Unamplified Chromosome 17 Polysomy in Invasive Breast Carcinoma
(177)
U Krishnamurti, J Lindner, F Atem, P Storto, J Silverman - West Penn Hospital, Pittsburgh, PA; Allegheny General Hospital, Pittsburgh, PA; University of Pittsburgh, Pittsburgh, PA
High Interlaboratory Reproducibility of the Silver In Situ Hybridization Assay for the Detection of HER2 Gene Status in Breast Carcinoma: A Study Reporting Results from Five Cancer Institutes
(107)
A Carbone, G Botti, A Gloghini, G Simone, M Truini, P Verderio - Cancer Institute of Milan, Milan, Italy; G. Pascale Cancer Institute of Naples, Naples, Italy; Centro di Riferimento Oncologico, Aviano, Italy; Ospedale Oncologico, Bari, Italy; Cancer Institute of Genoa, Genoa, Italy
Silver In-Situ Hybridization for Detection of HER2 Amplification in Breast Carcinoma: International Inter-Observer Interpretive Reproducibility Study of 305 Cases
(211)
B Papouchado, J Myles, R Lloyd, M Stoler, A Oliveira, E Downs-Kelly, N Prescott, L Dragovich, A McElhinny, M Loftus, J Pettay, F Gaire, C Roberts, M Dietel, T Grogan, R Tubbs - Cleveland Clinic, Cleveland, OH; Mayo Clinic, Rochester, MN; University of Virginia, Charlottesville, VA; Ventana Medical Systems, Tucson, AZ; Charite University Hospital, Berlin, Germany
Effect of ASCO/CAP Recommended Guideline for Positive Her2/neu Stain on FISH Concordance - An Evidence Based Study
(114)
AM Dastane, R Alsabeh, S Bose - Cedars-Sinai Medical Center, Los Angeles, CA
Chromogenic In Situ Hybridization Is a Reliable Method for Detecting HER-2 Gene Status in Breast Cancer: A Multicenter Study Comparing Three Methods
(140)
Y Gong, W Sweet, YJ Duh, L Greenfield, Y Fang, J Zhao, E Tarco, WF Symmans, J Isola, N Sneige - UT M. D. Anderson Cancer Center, Houston, TX; Invitrogen Corporation, Camarillo, CA; StatServ Consulting, Inc., Chino Hills, CA; Institute of Medical Technology, University of Tampere, Tampere, Finland
Impact of Chromosome 17/HER-2 Polysomy on Reliability of Chromogenic In Situ Hybridization: A Study of Two Institutions
(138)
Y Gong, W Sweet, YJ Duh, L Greenfield, WF Symmans, J Isola, N Sneige - UT MD Anderson Cancer Center, Houston, TX; Invitrogen Corporation, Camarillo, CA; StatServ Consulting, Inc, Chino Hills, CA; Institute of Medical Technology, University of Tampere, Tampere, Finland
HER2 Gene Amplification in Breast Carcinoma: A Methods Comparison Study between Silver In Situ Hybridization and FISH
(210)
B Papouchado, N Prescott, L Dragovich, A McElhinny, C Ferrell, M Loftus, J Pettay, P Roche, T Grogan, R Tubbs - Cleveland Clinic Foundation, Cleveland, OH; Ventana Medical Systems, Inc., Tucson, AZ
Biophenotype of Pleomorphic Lobular Carcinoma In Situ on Core Needle Biopsies
(158)
DM Haynik, M Chivukula, A Brufsky, G Carter, DJ Dabbs - Magee Woman's Hospital, Pittsburgh, PA; Magee Woman's Hopsital, Pittsburgh, PA
Nuclear Grade and Survival in Invasive Lobular Carcinoma: A Study with Long-Term Follow-Up
(73)
AL Adams, Y Li, O Hameed - University of Alabama at Birmingham, Birmingham, AL
Serial Analysis of Gene Expression of Lobular Carcinoma In Situ Identifies Upregulation of Metalloproteinase MMP-9 and Downregulation of Tight Junction Protein Claudin 4
(106)
D Cao, K Polyak, C Iacobuzio-Donahue, M Goggins, X Wu, S Sukumar, J Hicks, A De Marzo, P Argani - Johns Hopkins Medical Institutions, Baltimore, MD; Dana Farber Cancer Institute, Boston, MA
Comparative Genomic Hybridization Identifies High Frequency Chromosomal Alterations in Adenoid Cystic Carcinoma of the Breast
(222)
JT Rabban, S Lim, MF Lerwill, YY Chen, RC Jordan - UCSF, San Francisco, CA; Massachusetts General Hospital, Boston, MA
Adenoid Cystic Carcinomas of the Breast Express ER a - 36, a Novel Variant of Human Estrogen Receptor - a 66
(130)
Z Gatalica, H Deng, S Grazio, J Lamovec, J Palazzo, ZY Wang - Creighton University School of Medicine, Omaha, NE; Institute of Oncology, Ljubljana, Slovenia; Thomas Jefferson University, Philadelphia, PA
Mammary Adenoid Cystic Carcinoma: A Biologically Triphasic Neoplasm of Luminal, Myoepithelial and Non-Committed CK14+, p63+ Basal Cells
(162)
CS Ho, PH Tan, GMK Tse - Singapore General Hospital, Singapore, Singapore; Chinese University of Hong Kong, Hong Kong, Hong Kong
Molecular Analysis of KIT and Epidermal Growth Factor Receptor in Adenoid Cystic Carcinoma of the Breast
(198)
C Matte, JA Gilbert, HA Blair, MP Goetz, MM Ames, RB Jenkins, C Reynolds - Charles Lemoyne Hospital, Montreal, QC, Canada; Mayo Clinic, Rochester, MN
button next to any title to add to Itinerary Planner...
Add
